Palantir Technologies (PLTR)
(Delayed Data from NYSE)
$42.00 USD
+0.07 (0.17%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $41.95 -0.05 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
PLTR 42.00 +0.07(0.17%)
Will PLTR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PLTR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PLTR
The Zacks Analyst Blog Highlights NVIDIA, Palantir Technologies, Microsoft, Meta Platforms and Advanced Micro Devices
Palantir Technologies Inc. (PLTR) Stock Falls Amid Market Uptick: What Investors Need to Know
PLTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bull Market Completes 2 Years on AI Surge; NVIDIA & PLTR Stocks Shine
5 Single Stock ETFs That Ruled Last Week
Can BigBear.ai's Expanding Federal Clientele Push the Stock Higher?
Other News for PLTR
SPY ETF Update, 10/17/2024???
Making Sense Of Palantir's Current Valuation
Peeling Back The Layers: Exploring Palantir Technologies Through Analyst Insights
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
Palantir price target raised by $6 at Mizuho, here's why